cyrilzakka/clinical-trials huggingface dataset:
To Evaluate the Efficacy and Safety of Shampoo TD03 and TD07 in Scalp Diseases

Scalp Conditions are common chronic skin inflamations with the occurence rate of 1 - 5 % among the population. TD03 shampoo and TD07 shampoo are widely used to avoid hair loss with successful rate reaching nearly 95%. This trial is going to evaluate the efficacy of getting rid of dandruff as well as the safety of the investigational products in comparison to a reference (ketoconazole 2%) during a 4-week treatment period.

Scalp Conditions are common chronic skin inflamations with the occurence rate of 1 - 5 % among the population. TD03 shampoo and TD07 shampoo are widely used to avoid hair loss with successful rate reaching nearly 95%. With herbal ingredients including Gleditsia, Morus alba, Ocimum tenuiflorum, Oroxylum indicum, Ageratum conyzoides, the investigational products could reduce the severity of inflamation, infection and help to prevent hair loss. This trial is planning to evaluate the efficacy of the IPs in terms of inflamation reduction, dandruff reduction on subjects using the IPs compared to a reference (ketoconazole 2%).

The trial is intended to last for 18 months with subject visits and 3 arms (122 subjects per arm). The first arm receive TD3 while TD7 is provided to the second arm in comparison to the placebo of the last arm. It will be conducted at National Hospital of Dermato - Venerology, Vietnam.

Eligibility Criteria:
Inclusion Criteria:

* \> 18 years old and signed the ICF.
* Diagnosed with head skin inflamtion with IGA \<= 3.
* Voluntary sign the ICF before any procedures.
* No hypersentivity to the IP.

Exclusion Criteria:

* Use oral antifungal 1 month prior to the trial participation or topical antifungal 2 weeks prior to the trial participation.
* Suffering chronic or acute diseases that may affect the trial.
Pilot of a Trial Enrollment Diversity Dashboard

The goal of this study is to test the feasibility of a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) to ensure participant diversity in acute leukemia trial enrollment.

This study is about testing a tool called the Trial Enrollment Diversity Dashboard (TEDD) to see if it can help increase diversity in cancer clinical trials, specifically for leukemia. Clinical trials are important for developing new cancer treatments, but not all groups are equally represented in these trials. This can lead to treatments that may not work as well for everyone.

The TEDD tool is designed to give medical professionals feedback on how diverse their patient enrollments are clinical trials. By using this tool, medical professionals can see if they are enrolling a diverse group of patients and make changes if needed.

The study will involve a small group of medical professionals who treat leukemia patients. They will use the TEDD tool and provide feedback on its usability and effectiveness. Study procedures include completion of surveys and usage of the TEDD intervention dashboard.

It is expected that about 12 medical professionals will take part in this research study. Participation in this research study is expected to last about 14 months.

The National Cancer Institute is providing funding for this research study.

Eligibility Criteria:
Inclusion Criteria Medical Professionals:

* Physician, nurse practitioner, or physician assistant

  -≥10% clinical effort (or one ½ day of clinic per week for those working \<1 FTE)
* Treats adult patients with leukemia or related diseases at the study sites
* Ability to understand and willingness to provide informed consent
* Age 18 or older

Inclusion Criteria Participant Population:

* Age ≥18 years old
* Diagnosis of leukemia, lymphoma, myeloma, or related diseases
* Seen by a physician for this diagnosis at one of the study sites

Exclusion Criteria Medical Professionals:

-Listed member of the research team

Exclusion Criteria Participant Population:

-Participants without the diagnoses of interest listed above, participants not seen at the study sites.
Exploratory Study on Artifact Denoising of Cerebral Blood Flow and EEG Data in Ambulance Settings

The purpose is to assess the extent of digital noise occurring during the measurement of cerebral blood flow and EEG in healthy adults within an ambulance setting and to explore the possibility of identifying and correcting abnormal patterns.


Eligibility Criteria:
Inclusion Criteria:

* Healthy adults aged 19 to 80 years.
* Individuals without chronic diseases (e.g., Stage 2 hypertension, cardiovascular disease, chronic kidney disease, chronic pulmonary disease, etc.).
* Individuals without mental health disorders (e.g., depression, schizophrenia, etc.).
* Individuals not taking medications that could affect cerebral hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, antidepressants, etc.

Individuals who can read and understand the participant information and consent form and have sufficient language ability to respond to questionnaires.

- Individuals who voluntarily decide to participate in the clinical study, provide written consent on the participant consent form, and are able to participate throughout the entire duration of the clinical study.

Exclusion Criteria:

* Individuals who have experienced head trauma in the past 6 months.
* Individuals with ongoing severe chronic diseases (e.g., heart failure, chronic kidney disease, chronic pulmonary disease, etc.).
* Individuals with severe mental health disorders such as schizophrenia, severe depression, bipolar disorder, etc.
* Individuals currently taking medications that may affect the study (e.g., antihypertensives, anticoagulants, antiplatelets, antidepressants, etc.).
* Individuals who have participated in a clinical trial and taken experimental drugs within the past 30 days.
* Women who are pregnant or breastfeeding.
* Individuals who have undergone major surgery in the past 6 months.
* Individuals with acute infections or inflammatory diseases.
* Individuals with cognitive impairment or dementia.
* Individuals with neurological disorders.
* Individuals who lack understanding of the study procedures or who have not voluntarily consented to participate.
* Individuals with clinically significant findings that the study principal investigator or responsible medical personnel determines to be inappropriate for participation in this study.
CanRestoreFunction Cancer-related Fatigue ( CRF )

The goal of this randomized control trial is to determine if participating in an 8-week online cancer-related fatigue management intervention consisting of individualized exercise program, one-on-one goal setting and action plan development and interactive educational module will significantly reduce the perception of cancer-related fatigue, improve the quality of life, improve perceived cognition, and perceived function of breast cancer compared to a wait-list control group. The aim the project is to determine if an online cancerrelated fatigue management program is associated with 1. A decrease in cancer-related fatigue. 2. An improved perception of their ability and satisfaction in completing important activities 3. Greater quality of life. 4. Improved mobility 5. Improved perceived cognition


Eligibility Criteria:
Inclusion Criteria:

* been diagnosed with any type of cancer within 5 years of enrollment,
* received chemotherapy and/or radiation therapy
* have access to mobile device or computer
* have basic computer or mobile device skills,
* have a significant level of fatigue defined as \>3 on 0-10 scale using the Oneitem Fatigue Scale

Exclusion Criteria:

* have metastatic cancer (Stage 4),
* do not have a signed medical release by their physician or physician extender indicating that the participant can safely participate in the exercise program,
* chronic fatigue prior to cancer diagnosis, such as fibromyalgia
* are unable to follow verbal or written assessment instructions, are non-English speaking
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years. The different research focusses are:

* Identification of clinical parameters and patient characteristics / host-related factors in long-term survivors (Focus 1)
* Identification of molecular tumor characteristics in long-term survivors (Focus 2)
* Assessment of therapy-related parameters, including neuro-toxicity (Focus 3)
* Immunological studies (Focus 4)


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years at diagnosis
* Histopathological diagnosis of glioblastoma (reference histology available) and
* Survival \>5 years from diagnosis
* Availability of tumor tissue from initial glioblastoma diagnosis (FFPE or fresh-frozen) to validate the diagnosis centrally.
* Signed consent form (living patients) or ethics approval for anonymous data collection in case of retrospective analysis of deceased patients

Exclusion Criteria:

* Not applicable
Neuromuscular Blocking Agents in the Elderly

The number of elderly patients (\>80 years) is increasing and a large proportion of these patients will require surgery and anaestheasia within the next decades.

During anaesthesia NMBAs are used to facilitate tracheal intubation, from former studies it is reported that elderly patients are more sensitive towards muscle relaxants.

It is unknown if there are differences in onset times of NMBAs between younger patients and elderly.

The aim of this study is to determine the onset time, duration of action and effect on intubating conditions for rocuronium 0.6 mg/kg in patients aged 18-40 years and in patiens \>80 years. The hypothesis of this study is that rocuronium administered in elderly patients (\>80 years) has a longer onset time compared to younger patients.

The number of elderly patients (\>80 years) is increasing and a large proportion of these patients will require surgery and anesthesia within the next decades. Elderly patients are at higher risk of major morbidity and mortality and are characterized by a reduction in cardiac output, liver function and renal function. These physiological changes influence pharmacodynamics and pharmacokinetics of drugs administered during anesthesia as for example neuromuscular blocking agents (NMBA).

During anesthesia NMBAs are used to facilitate tracheal intubation, establish muscle relaxation and suppress reflexes during surgery. Elderly patients are more sensitive towards muscle relaxants. In addition studies have reported prolonged duration of NMBAs and an observational study found that elderly patients are more prone to experience residual neuromuscular blockade in the post anesthesia care unit. However, most studies have been conducted in elderly below 80 years.

It is unknown if there are differences in onset times of NMBAs e.g. rocuronium, mivacurium and cisatracurium between younger patients and elderly. Onset time for NMBAs in the elderly is of importance since it may influence intubating conditions, especially during rapid sequence induction. For example it is unknown in the elderly if an increased dose of NMBA reduces the onset time. There remains a need for studies investigating the optimal dose for facilitating intubation in the elderly, both during rapid sequence induction and during elective procedures.

The aim of this study is to determine the onset time, duration of action and effect on intubating conditions for rocuronium 0.6 mg/kg in patients aged 18-40 years and in patients with age \> 80 years. The hypothesis of this study is that rocuronium administered in elderly patients (\>80 years) has a longer onset in the elderly compared to younger patients.

Eligibility Criteria:
Inclusion Criteria:

* Patients \> 18 years old
* Informed consent
* Scheduled for elective surgery (\>1 hour) under general anaesthesia with intubation and use of rocuronium.
* American Society of Anaesthesiologists (ASA) physical status classification I to III
* Can read and understand Danish

Exclusion Criteria:

* Known allergy to rocuronium
* Neuromuscular disease that may interfere with neuromuscular data
* Indication for rapid sequence induction
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This study will have 5 treatment arms (4 active and 1 placebo).


Eligibility Criteria:
Inclusion Criteria:

1. Male or female patients with a clinical diagnosis of AD for at least 1 year;
2. vIGA score of ≥3 at Screening and Baseline;
3. ≥10% BSA of AD involvement at Screening and Baseline;
4. EASI score ≥16 at Screening and Baseline;
5. History of inadequate response to treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI);
6. Twice daily application of a consistent amount of topical emollient for at least 7 days prior to randomization.

Exclusion Criteria:

1. Immunosuppressive/immunomodulating drugs, systemic therapies or phototherapy within 4 weeks prior to randomization;
2. Treatment with leukotriene inhibitors within 4 weeks prior to randomization;
3. Treatment with topical therapies (including TCS, TCI, topical phosphodiesterase inhibitors, topical JAK inhibitors) or prescription moisturizers, within 1 week prior to randomization;
4. Previous treatment at any time prior to randomization with monoclonal antibody / biologic therapeutic agents as follows;

   1. Prior exposure to dupilumab (Dupixent®) which was discontinued due to lack of efficacy, loss of response, or adverse event;
   2. Investigational or approved agents targeting interleukins IL-4 or IL-13 ligands or receptors of IL-4 or IL-13, including but not limited to lebrikizumab, tralokinumab or ASLAN004;
   3. Other investigational or approved biologic drug within 16 weeks or within 5 half-lives (if known), whichever is longer, prior to the Baseline visit;
   4. Cell-depleting biologics, including, but not limited to, rituximab within 6 months prior to the Baseline visit;
5. Inadequate organ function, abnormal lab result, uncontrolled blood pressure or other health condition considered clinically significant by the investigator at the Screening visit;
6. History of HIV, Hepatitis B, Hepatitis C or active/latent Tuberculosis infection;
7. History of immunosuppression including history of invasive opportunistic infections;
8. Treatment with live attenuated vaccine within 8 weeks prior to randomization;
9. Parasitic infection within 4 weeks prior to baseline travel within 3 months prior to randomization to areas of high parasitic exposure;
10. Have skin comorbidities that in the opinion of the Investigator may interfere with study assessments;
11. Pregnant or breastfeeding women;
12. Patients unwilling to use adequate birth control.
13. Active COVID infection at baseline.
Assessment of Two Levels of Arterial Pressure on Survival in Patients With Septic Shock

The ideal mean arterial pressure in patients with septic shock is unknown. The expert's recommandations have stated a target between 65 and 70 mm Hg. However the scientific basis are weak. Indead there are only few prospective studies which addressed this question without clear answer. Therefore we designed a RCT in order to assess the effect on mortality of two levels of mean arterial pressure in patients with septic shock.(800 patients, 30 centres)


Eligibility Criteria:
Inclusion Criteria:

* patients with septic shock according criteria of Bone
* minimal dose of norepinephrine
* Written informed consent obtained from the patient or surrogate

Exclusion Criteria:

* Age \< 18 years
* Pregnancy
* Participation in other trials with the same endpoints
* moribund
* absence of registration in french health care system
* patient protected by law
Imaging of Joint Replacement Complications by PET/CT

Total hip replacement is the well-established surgical method for treatment of hip osteoarthritis and related diseases. The outcome of the procedure is commonly satisfactory and most patients will not need any revision surgery. However, the procedure has its complications, including (1) periprosthetic infection, (2) mechanical loosening caused by wear particles and (3) adverse reaction caused by metal ions released from metal-on-metal bearing surfaces. The unsolved clinical problem is related to the differential diagnosis of these conditions. The purpose of this prospective clinical study is to compare the efficacy of two techniques of PET/CT imaging in the differential diagnosis of these complications. Positron Emission Tomography (PET)/Computed Tomography (CT) imaging, performed during a single day, will include the head-to-head comparison of 18F-Fluoro-D-Glucose (18F-FDG) PET/CT and 68Gallium-citrate (68Ga-citrate) PET/CT imaging.

(68Ga) gallium citrate is a novel PET tracer aimed for detection of skeletal infections. It has not been previously applied to diagnose periprosthetic joint infections in arthroplasty patients. This exploratory prospective study, representing the first of its kind, examines the use of 68Ga-citrate as a diagnostic tool of periprosthetic infections aside with 18F-FDG tracer as the standard reference.

The first study group (n=10) will include total hip replacement patients without infection. The recruited patients should suffer from pain and/or functional impairment due to adverse reaction to metal debris (ARMD) caused by metal-on-metal bearings. The diagnosis of ARMD should be based on metal artifact reduction sequence magnetic resonance imaging (MARS-MRI). The patients will undergo the same-day comparison of the two PET/CT tracers.

The second study group (n=10) will include total hip replacement patients with bacteriologically confirmed periprosthetic joint infection. The third group (n=10) will include patients with aseptic loosening of total hip prosthesis.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients with uncemented total hip replacement
* American Society of Anesthesiology score I-III
* Group 1: local symptoms and MRI findings of the operated hip fulfilling the criteria of ARMD due to metal-on-metal bearings of the hip prosthesis, infection ruled out
* Group 2: bacteriologically verified periprosthetic infection of the hip prosthesis
* Group 3: local symptoms and radiographic findings of the hip prosthesis fulfilling the criteria of aseptic mechanical implant loosening, infection ruled out

Exclusion Criteria:

* any related condition of the index hip which requires immediate surgical intervention, such as a septic infection or a periprosthetic fracture
* any systemic disorder or condition (ASA IV) which makes the patient an unlikely candidate for revision surgery of the affected hip implant
Effect of Lidocaine in Reducing Opioids Requirement in Day Care Surgery

1. \*Reduced opioid consumption
2. \*Decreased pain scores
3. \*Fewer opioid-related side effects
4. \*Improved patient satisfaction

Studies have shown that lidocaine can reduce opioid consumption by 20-50% in the perioperative period.

Studies have shown that lidocaine can reduce opioid consumption by 20-50% in the perioperative period.

By reducing opioid consumption, lidocaine can also decrease the incidence of opioid-related side effects, such as nausea, vomiting, and respiratory depression.

Lidocaine's analgesic effects can improve patient satisfaction and reduce anxiety related to pain

Eligibility Criteria:
Inclusion Criteria:

* ASA 1 and 2
* patient age between 18 and 65 years
* Patient undergoing ambulatory surgeries

Exclusion Criteria:

* Pregnant women
* Allergic to Lidocaine Patient who had fever and treated with antibiotic and steroid in last month
ALN OATF Vena Cava Filter

Migration of a thrombus in the pulmonary circulation is the leading cause of pulmonary embolism (PE). It can be prevented mechanically by implanting a vena cava filter (VCF) in the inferior vena cava. The implation of a VCF is indicated for patients with acute PE and a contraindication to anticoagulation, with an acute deep vein thrombosis (DVT) without PE and a contraindication to anticoagulation or with acute venous thromboembolism (less than 3 months) in whom an interventional gesture at hemorrhagic and thromboembolic risk contraindicates anticoagulation.

The purpose of this study is to describe the rates of implantation, removal and complications associated with the use of the optional ALN OATF VCF in current practice.


Eligibility Criteria:
Inclusion Criteria:

* Patient implanted with an ALN OATF VCF
* Patient informed

Exclusion Criteria:

* Minor patient
* Adult patient under a legal protection measure
* Pregnant, parturient or breastfeeding women
* Patient who refused to participate
* Patient who cannot or does not wish to be followed by the Interventional Radiology Department
Health in Individuals With a Spinal Cord Injury: a Prospective Study

Individuals with a spinal cord injury need to exercise regularly to prevent the decline of health that results from a sedentary lifestyle. The purpose of this investigation is to examine the effects of a pre-existing exercise program and respiratory training on measures of health and quality of life in individuals who elect to participate in an existing 8-week supervised exercise program.

The life expectancy of individuals with spinal cord injuries (SCI) has increased over the past decade. Yet, this population continues to present with an increased risk of a number of secondary health conditions, many of which occur sooner and at a higher rate than the normative population. As a program established to address this post-rehabilitative exercise participation necessity, it is determined that the Spinal Mobility fitness program, if found effective, can have vast positive effects in addressing aspects of health, function fitness, and overall quality of life for individuals with SCI. In addition to the need for exercise respiratory training is an important component of prevention of illness in individuals with a spinal cord injury. Genitourinary, skin disease and respiratory disorders are the top 3 reasons. Developing effective respiratory training programs in addition to exercise programs are critical for the prevention of illness and enabling a high quality of life. Pneumonia and septicemia are the two leading causes of decreased life expectancy in this population. Adding respiratory training to the spinal mobility program would be an appropriate intervention to further prevent health decline in these individuals.The spinal mobility course runs for eight weeks two times each year for 8 sessions for 4 to 5 hours each on Saturdays. Additionally individuals can participate in spinal mobility fitness training up to 3 times a week for one to three hours.

Eligibility Criteria:
Inclusion Criteria:

* 18 years and older
* Individuals with spinal cord injury
* Medically stable
* Able to participate in the spinal mobility program

Exclusion Criteria:

* Individual with spinal cord injury who is medically unstable
* Cannot participate in an exercise program